Asthma and COPD Drugs Market | USD 59562.82 Million by 2034
The asthma and COPD drugs market size was exhibited at USD 37807.93 million in 2024 and is projected to hit around USD 59562.82 million by 2034, growing at a CAGR of 4.65% during the forecast period 2025 to 2034.
Asthma is a chronic, non-communicable inflammatory lung condition affecting the airways. Hyper-responsiveness of the airways results in recurring episodes of wheezing, shortness of breath, chest tightness, and coughing. Unlike other obstructive lung diseases, asthma is largely reversible. The strongest risk factor for asthma is allergy. Additionally, asthma can be triggered by exposure to irritants, physical exertion, β-blockers, cold air, animals, and dust.
Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is not entirely reversible. COPD encompasses emphysema, a complex lung condition involving alveolar damage, and chronic bronchitis, which is marked by prolonged inflammation of the lower respiratory tract. Tobacco smoking is the primary cause of COPD, while passive smoking, occupational hazards, and air pollution also contribute to its development.
Diagnosis of asthma and COPD involves physical examinations and various tests, including X-rays, sputum eosinophil counts, and nitric oxide tests. Treatment options include inhaled corticosteroids, leukotriene modifiers, and theophylline. Acute respiratory attacks, however, can be managed using short-acting beta agonists and anticholinergic medications.
The global market for asthma and COPD drugs is experiencing growth due to the increasing prevalence of these respiratory conditions. According to the World Health Organization (WHO), asthma affected an estimated 262 million individuals and was responsible for 461,000 deaths in 2019. Additionally, the rising number of COPD cases is driving market expansion. For instance, the American Lung Association reported that in 2018, 99 million adults in the U.S. had chronic bronchitis, while 2 million adults had emphysema.
Furthermore, advancements in respiratory disease treatments and the introduction of new products are expected to propel market growth. In December 2020, AstraZeneca, a leading pharmaceutical company, secured EU approval for ‘Trixeo Aerosphere’ as a maintenance therapy for COPD. However, the high cost of asthma treatment remains a key challenge, potentially limiting market growth in the coming years.
The Asthma and COPD Drugs Market is segmented based on disease type, medication class, and geographic region. By disease type, the market is primarily divided into asthma and COPD.
In terms of medication class, the market is categorized into combination drugs, inhaled corticosteroids (ICS), short-acting beta agonists (SABA), long-acting beta agonists (LABA), leukotriene antagonists (LTA), anticholinergics, and others.
Regionally, the Asthma and COPD Drugs Market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and the rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and the rest of LAMEA).
By disease type, the asthma segment held the largest market share in 2024 and is expected to maintain its dominance throughout the forecast period due to the growing number of asthma patients. However, the COPD segment is anticipated to experience substantial growth, driven by advancements in COPD treatment.
Based on medication class, combination drugs were the leading contributors in 2020 and are expected to continue leading the market due to the effectiveness and reliability of combination therapies. However, the inhaled corticosteroids segment is projected to grow significantly during the forecast period due to ongoing advancements in respiratory treatments.
From a regional perspective, North America accounted for the largest share of the Asthma and COPD Drugs Market in 2020 and is expected to retain its dominance, driven by the rising prevalence of asthma, presence of major pharmaceutical manufacturers, increasing tobacco consumption, and well-established healthcare infrastructure. However, the Asia-Pacific region is projected to exhibit the highest compound annual growth rate (CAGR) of 5.81% from 2021 to 2030, attributed to the growing number of hospitals and a large patient population.
This report provides a detailed analysis of the global Asthma and COPD Drugs Market size, highlighting current trends and future projections to identify potential investment opportunities.
It presents an in-depth market analysis from 2025 to 2034, allowing stakeholders to capitalize on emerging opportunities.
A comprehensive regional analysis helps in understanding market dynamics and aids strategic business planning by identifying key growth prospects.
The competitive landscape is thoroughly examined, including profiles and growth strategies of key industry players, offering valuable insights into market positioning and future developments.
Asthma and COPD are respiratory disorders primarily identified by breathing difficulties.
The market is driven by both conditions, with asthma currently leading due to the increasing prevalence of asthma cases and rising air pollution levels.
Key growth factors include the increasing incidence of respiratory diseases, expansion of healthcare facilities, and continuous advancements in asthma and COPD treatment. Additionally, government initiatives aimed at improving patient care and quality of life are expected to further fuel market expansion.
North America is projected to generate the highest revenue, driven by the high prevalence of respiratory conditions, the presence of leading pharmaceutical manufacturers, and the increasing number of hospitals and diagnostic centers.
However, challenges such as the high cost of asthma and COPD treatments and inadequate healthcare infrastructure in certain regions may impede market growth during the forecast period.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Asthma and COPD Drugs Market
5.1. COVID-19 Landscape: Asthma and COPD Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Asthma and COPD Drugs Market, By Diseases
8.1. Asthma and COPD Drugs Market, by Diseases Type, 2023-2032
8.1.1. Asthma
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. COPD
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Asthma and COPD Drugs Market, By Medication Class
9.1. Asthma and COPD Drugs Market, by Medication Class, 2023-2032
9.1.1. Combination Drugs
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Bronchodilators
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Inhaled Corticosteroids (ICS)
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Short Acting Beta Agonists (SABA)
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Long Acting Beta Agonists (LABA)
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Leukotriene Antagonists (LTA)
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Anticholinergics
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Asthma and COPD Drugs Market, By Distribution Channel
10.1. Asthma and COPD Drugs Market, by Distribution Channel, 2023-2032
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Drug Stores
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Asthma and COPD Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.1.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.2.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.3.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Teva Pharmaceutical Industries Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co. Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Grifols S.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Cipla Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Abbott
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Astellas Pharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Hoffmann-La Roche Ltd
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Glenmark Pharmaceuticals
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers